Company News This week marks the official launch of Orthocell’s new GMP certified bio-manufacturing facility at the Company headquarters in Perth. 29 May 2023 New Bio-manufacturing Facility Launch Event This week marks the official launch of Orthocell’s new GMP certified bio-manufacturing facility at the Company headquarters in Perth. Orthocell
Company News 29 May 2023 Appointment of John Van Der Wielen as Independent Non-Executive Chairman Orthocell has announced the appointment of Mr. John Van Der Wielen as Orthocell’s new independent Non-Executive Chairman, effective June 1,… Orthocell
Company News 26 Apr 2023 Veritas Securities Equity Research Report | April 2023 Veritas Securities Limited has released an Equity Research report valuing Orthocell (ASX: OCC) at A$0.90 per share. The report summarises… Orthocell
Company News 18 Apr 2023 Commencement of Nerve Repair Study Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory… Orthocell
Company News 29 Sep 2022 Ortho-ATI™ Shoulder Tendon Study Update Orthocell has today shared positive results from the crossover extension arm of our randomised clinical trial examining the performance of… Orthocell
Company News 27 Sep 2022 First orders for dental and nerve products Orthocell has now received first purchase orders for our flagship collagen medical device products Striate+™ and Remplir, via our valued… Orthocell
Company News 07 Sep 2022 Appointment of exclusive distributor of Remplir™ in Australia Orthocell has appointed Device Technologies as the exclusive distributor of Remplir™ for peripheral nerve repair in Australia. Orthocell
Company News 27 Jun 2022 Striate+™ global exclusive license and manufacturing agreement with BioHorizons Orthocell (ASX:OCC) has signed a global exclusive license and manufacturing agreement for its FDA-cleared dental product, Striate+™, with BioHorizons Implant… Orthocell
Company News 29 Apr 2022 Quarterly Report | Period To 31 March 2022 Orthocell has today published its Quarterly Report for the period ended 31 March 2022. Standout achievements for this Quarter include:… Orthocell
Company News 21 Mar 2022 TGA Approval for Remplir™ Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval. Orthocell